GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
NASDAQ:CATB
Delisted

Catabasis Pharmaceuticals Stock Price (Quote)

$3.36
+0.195 (+6.16%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $3.02 $6.17 Friday, 27th May 2022 CATB stock ended at $3.36. This is 6.16% more than the trading day before Thursday, 26th May 2022. During the day the stock fluctuated 6.65% from a day low at $3.16 to a day high of $3.37.
90 days $3.02 $7.25
52 weeks $1.20 $10.26

Historical Catabasis Pharmaceuticals prices

Date Open High Low Close Volume
2019-05-02 $7.69 $7.80 $7.30 $7.55 73 719
2019-05-01 $7.52 $7.64 $7.33 $7.58 56 583
2019-04-30 $7.82 $7.98 $7.49 $7.51 105 462
2019-04-29 $7.90 $8.08 $7.75 $7.82 54 474
2019-04-26 $7.80 $7.88 $7.42 $7.88 89 927
2019-04-25 $8.05 $8.05 $7.66 $7.86 113 001
2019-04-24 $8.22 $8.38 $8.06 $8.12 50 472
2019-04-23 $8.25 $8.51 $8.13 $8.18 102 462
2019-04-22 $8.04 $8.37 $7.98 $8.28 77 676
2019-04-18 $8.22 $8.22 $7.90 $8.10 146 364
2019-04-17 $8.37 $8.42 $7.85 $8.20 159 655
2019-04-16 $8.55 $8.75 $7.74 $8.32 315 213
2019-04-15 $9.03 $9.13 $8.30 $8.51 216 805
2019-04-12 $9.05 $9.56 $8.88 $9.01 208 894
2019-04-11 $9.76 $9.76 $8.73 $8.99 394 210
2019-04-10 $8.76 $9.70 $8.75 $9.64 300 411
2019-04-09 $8.82 $8.90 $8.60 $8.71 151 649
2019-04-08 $8.58 $9.29 $8.50 $8.85 180 998
2019-04-05 $8.29 $8.67 $8.27 $8.54 168 622
2019-04-04 $8.21 $8.38 $8.11 $8.37 118 377
2019-04-03 $7.73 $8.39 $7.68 $8.12 235 225
2019-04-02 $7.67 $7.84 $7.45 $7.74 105 728
2019-04-01 $7.92 $8.09 $7.57 $7.68 185 404
2019-03-29 $7.30 $7.92 $6.99 $7.92 275 601
2019-03-28 $7.37 $7.72 $7.30 $7.56 179 055
Click to get the best stock tips daily for free!

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy (DMD); CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia i... CATB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT